CLINICAL TRIALS PROFILE FOR PF-07081532
Clinical Trials for PF-07081532
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT04148209 ↗ | Study of Single Ascending Doses of PF-07081532 in Healthy Adult Participants | Completed | Pfizer | Phase 1 | The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of single ascending oral doses of PF-07081532 in healthy adult participants. |
| NCT04305587 ↗ | Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus | Completed | Pfizer | Phase 1 | This is a randomized, placebo-controlled, double-blind (investigator- and participant-blinded), sponsor-open, dose-escalating study of PF-07081532 in patients with Type 2 diabetes on metformin (Parts A and C). The study may also enroll non-diabetic participants with obesity (Part B). Study participants will receive an investigational product or placebo every day for up to 28 days (Part A) or up to 42 days (Part B, optional; Part C, optional). The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple oral doses of PF-07081532 in participants with inadequately controlled T2DM on metformin and optionally in non-diabetic obese participants. |
| NCT05158244 ↗ | A Phase 1 Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus | Not yet recruiting | Pfizer | Phase 1 | This is a Phase 1, randomized, placebo-controlled, double-blind (investigator- and participant-blinded), sponsor-open study of PF-07081532. Study participants will receive the investigational product or placebo every day for 42 days. The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of multiple oral doses of PF-07081532 in participants with inadequately controlled type 2 diabetes mellitus, on metformin and optionally in non-diabetic participants with obesity. |
| NCT05478603 ↗ | A Study to Investigate the Effects of Hepatic Impairment on the Pharmacokinetics of PF-07081532 | Not yet recruiting | Pfizer | Phase 1 | The primary purpose of this study is to characterize the effect of varying degrees of hepatic impairment on the plasma pharmacokinetics (PK) of PF-07081532 following administration of a single oral dose of PF-07081532. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for PF-07081532
Condition Name
Clinical Trial Locations for PF-07081532
Trials by Country
Clinical Trial Progress for PF-07081532
Clinical Trial Phase
Clinical Trial Sponsors for PF-07081532
Sponsor Name
